Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.

Oramed Pharmaceuticals Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PAYMENT CLOSES OUT OPTION AGREEMENT OBLIGATIONS; ORAMED RETAINS $39 MILLION OUTSTANDING DEBT, CONVERTIBLE DEBT, WARRANTS, AND AN ONGOING ROYALTY INTEREST NEW YORK, JAN. 7, 2026 /PRNEWSWIRE/ -- ORAMED PHARMACEUTICALS INC. (NASDAQ: ORMP) (TASE: ORMP) TODAY ANNOUNCED IT HAS RECEIVED AN $18 MILLION PAYMENT FROM SCILEX HOLDINGS INC., REPRESENTING FULL SATISFACTION OF OBLIGATIONS UNDER THE OPTION AGREEMENT. THIS PAYMENT BRINGS ORAMED'S CURRENT RETURNS TO $118 MILLION ON ITS ORIGINAL $99.5 MILLION SCILEX INVESTMENT, WITH ADDITIONAL RETURNS EXPECTED FROM THE REMAINING CONVERTIBLE NOTES, WARRANTS, AND ROYALTIES.

ORAMED RECEIVES $18 MILLION PAYMENT FROM SCILEX HOLDINGS, BRINGING CURRENT RETURNS TO $118 MILLION; BOARD APPROVES DIVIDEND PAYMENTS

STRONG NINE-MONTH PERFORMANCE DRIVEN BY STRATEGIC INVESTMENT PORTFOLIO; TOTAL ASSETS INCREASE 42% TO $220.5 MILLION NEW YORK , NOV. 17, 2025 /PRNEWSWIRE/ --ORAMED PHARMACEUTICALS INC. (NASDAQ:ORMP) (TASE: ORMP), A PLATFORM TECHNOLOGY PIONEER IN THE FIELD OF ORAL DELIVERY SOLUTIONS FOR DRUGS CURRENTLY DELIVERED VIA INJECTION, TODAY ANNOUNCED ITS UNAUDITED FINANCIAL RESULTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025. NINE-MONTH PERIOD 2025 FINANCIAL HIGHLIGHTS: NET INCOME (PRE-TAX) OF $65.0 MILLION , COMPARED TO A NET LOSS OF $6.1 MILLION IN THE SAME PERIOD LAST YEAR COMPLETED FULL REPAYMENT FROMSCILEX: RECEIVED APPROXIMATELY $27 MILLION DURING THE PERIOD, BRINGING TOTAL REPAYMENT TO $100 MILLION AND REPRESENTING FULL RETURN OF PRINCIPAL FROM THE COMPANY'S STRATEGIC INVESTMENT STRONG PER-SHARE PERFORMANCE: BASIC EARNINGS PER SHARE OF $1.30; DILUTED EARNINGS PER SHARE OF $1.26 ROBUST BALANCE SHEET GROWTH: TOTAL ASSETS INCREASED 42% FROM $155.3 MILLION TO $220.5 MILLION YEAR-OVER-YEAR OPERATING EXPENSES: R&D EXPENSES DECREASED FROM $4.9 MILLION TO $4.4 MILLION; G&A EXPENSES INCREASED FROM $4.3 MILLION TO $5.0 MILLION THE SIGNIFICANT IMPROVEMENT IN NET INCOME WAS PRIMARILY DRIVEN BY THE COMBINATION OF REALIZED CASH RETURNS FROM SCILEX HOLDING COMPANY AND SUBSTANTIAL UNREALIZED FAIR-VALUE GAINS FROM THE COMPANY'S EQUITY HOLDINGS IN ALPHA TAU MEDICAL LTD.

ORAMED REPORTS FISCAL THIRD QUARTER 2025 FINANCIAL RESULTS

NEW YORK , NOV. 17, 2025 /PRNEWSWIRE/ -- THE BOARD OF DIRECTORS OF ORAMED PHARMACEUTICALS INC. (THE "COMPANY") ANNOUNCED TODAY THAT IT HAS UNANIMOUSLY ADOPTED A RIGHTS AGREEMENT, DATED NOVEMBER 17, 2025 (THE "RIGHTS PLAN"), BY AND BETWEEN THE COMPANY AND CONTINENTAL STOCK TRANSFER & TRUST COMPANY, AS RIGHTS AGENT, AND DECLARED A DIVIDEND OF ONE COMMON STOCK PURCHASE RIGHT (A "RIGHT") ON EACH OUTSTANDING SHARE OF ITS COMMON STOCK, PAR VALUE $0.012 PER SHARE (THE "COMMON STOCK"), OF THE COMPANY. THE RIGHTS ARE DESIGNED TO ASSURE THAT ALL STOCKHOLDERS OF THE COMPANY RECEIVE FAIR AND EQUAL TREATMENT IN THE EVENT OF A HOSTILE TAKEOVER OF THE COMPANY, TO GUARD AGAINST TACTICS DESIGNED TO GAIN CONTROL OF THE COMPANY WITHOUT PAYING ALL STOCKHOLDERS A FAIR PRICE, AND TO ENHANCE THE BOARD'S ABILITY TO NEGOTIATE WITH ANY PROSPECTIVE ACQUIROR.

ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS

ORAMED ADVANCING ORAL INSULIN PROGRAM INDEPENDENTLY; ANNOUNCES LAUNCH OF NEW U.S. TRIAL DIVERSIFIED INVESTMENT PORTFOLIO DELIVERS STRONG RETURNS COMPANY ACCELERATING GROWTH THROUGH STRATEGIC PARTNERSHIPS, INNOVATION, AND VALUE-DRIVEN EXPANSION COMPANY REAFFIRMS COMMITMENT TO REWARDING SHAREHOLDERS, INCLUDING PLANS FOR A ONE-TIME DIVIDEND NEW YORK , OCT. 23, 2025 /PRNEWSWIRE/ -- ORAMED PHARMACEUTICALS INC. (NASDAQ: ORMP) (TASE: ORMP) ("ORAMED" OR THE "COMPANY" OR "WE"), A CLINICAL-STAGE PHARMACEUTICAL COMPANY, TODAY ISSUED A LETTER TO SHAREHOLDERS FROM ITS PRESIDENT AND CHIEF EXECUTIVE OFFICER, NADAV KIDRON. DEAR SHAREHOLDERS, I AM PLEASED TO SHARE WITH YOU SOME OF THE SIGNIFICANT DEVELOPMENTS WE HAVE SEEN ACROSS ORAMED'S OPERATIONS AND STRATEGIC INITIATIVES.

ORAMED RELEASES LETTER TO SHAREHOLDERS, HIGHLIGHTING DEVELOPMENTS IN ITS ORAL INSULIN PROGRAM, SIGNIFICANT INVESTMENT APPRECIATION, AND UPCOMING GROWTH INITIATIVES

ORAMED LEVERAGES ITS STRATEGIC CAPITAL MARKETS EXPERTISE TO SUPPORT ALPHA TAU'S BREAKTHROUGH CANCER THERAPY TECHNOLOGY ACCELERATING MULTIPLE LATE-STAGE CANCER THERAPIES INCLUDING: US CLINICAL TRIALS ACROSS FOUR INDICATIONS, MANUFACTURING SCALE-UP, AND COMMERCIALIZATION EFFORTS PARTNERSHIP UNITES TWO INNOVATIVE THERAPEUTIC DELIVERY PIONEERS  ORAMED'S ORAL DRUG DELIVERY PLATFORM WITH ALPHA TAU'S PRECISION RADIATION DELIVERY TECHNOLOGY NEW YORK , APRIL 28, 2025 /PRNEWSWIRE/ -- ORAMED PHARMACEUTICALS INC. ("ORAMED" OR THE "COMPANY"), (NASDAQ: ORMP) (TASE: ORMP), A PLATFORM TECHNOLOGY PIONEER IN THE FIELD OF ORAL DELIVERY SOLUTIONS FOR DRUGS CURRENTLY DELIVERED VIA INJECTION, ANNOUNCED TODAY THAT IT HAS SUCCESSFULLY CLOSED A STRATEGIC INVESTMENT IN ALPHA TAU MEDICAL LTD. (NASDAQ: DRTS), THE DEVELOPER OF THE INNOVATIVE ALPHA-RADIATION CANCER THERAPY ALPHA DART.

ORAMED PHARMACEUTICALS ANNOUNCES $36.9 MILLION INVESTMENT AND STRATEGIC COLLABORATION WITH ALPHA TAU MEDICAL

JERUSALEM, APRIL 28, 2025 (GLOBE NEWSWIRE) -- ALPHA TAU MEDICAL LTD. ("ALPHA TAU", OR THE COMPANY) (NASDAQ: DRTS, DRTSW), THE DEVELOPER OF THE INNOVATIVE ALPHA-RADIATION CANCER THERAPY ALPHA DART, ANNOUNCED TODAY THAT IT HAS SUCCESSFULLY CLOSED A REGISTERED DIRECT OFFERING (THE OFFERING) WHEREBY AN AFFILIATE OF ORAMED PHARMACEUTICALS INC. (ORAMED) (NASDAQ: ORMP) (TASE: ORMP) PURCHASED 14,110,121 OF ALPHA TAU'S ORDINARY SHARES, NO PAR VALUE, AT A PURCHASE PRICE OF $2.612 PER ORDINARY SHARE.

ALPHA TAU ANNOUNCES CLOSING OF $36.9 MILLION REGISTERED DIRECT OFFERING AND STRATEGIC MARKETING ALLIANCE WITH ORAMED PHARMACEUTICALS

KEY HIGHLIGHTS  EXPECTED COMPLETION IN YR 2025: ORATECH PHARMACEUTICALS INC. - A NEW JOINT VENTURE FOCUSED ON ORAL INSULIN DEVELOPMENT, WITH PLANNED U.S. PHASE 3 TRIALS. DISTRIBUTION OF MAJORITY OF ORAMED'S HOLDING IN ORATECH TO ORAMED SHAREHOLDERS VIA DIVIDEND PLANNED TO COINCIDE WITH ORATECH'S PUBLIC LISTING.

ORAMED PHARMACEUTICALS ISSUES LETTER TO SHAREHOLDERS

NEW STANDALONE COMPANY, ORATECH PHARMACEUTICALS INC., TO FOCUS ON ORAL DRUG DELIVERY WITH STRATEGIC INVESTMENT AND ADVANCED MANUFACTURING CAPABILITIES ORAMED SHAREHOLDERS TO RECEIVE THE RIGHT TO A DIRECT STAKE IN ORATECH, EXPECTED TO GO PUBLIC ON NASDAQ. ORATECH WILL HAVE GLOBAL MARKETING RIGHTS TO ORAMED'S POD ORAL PROTEIN DELIVERY TECHNOLOGY.

ORAMED ANNOUNCES TRANSFORMATIVE JOINT VENTURE TO ACCELERATE DEVELOPMENT AND COMMERCIALIZATION OF ORAL INSULIN

INITIATING PHASE 3 ORAL INSULIN TRIAL IN THE UNITED STATES UNDER A NEW PROTOCOL JV WITH CHINESE PARTNER, HTIT SCILEX SENIOR SECURED NOTE PERITECH ASSET PURCHASE & STRATEGIC OUT-LICENSING NEW YORK , FEB. 20, 2024 /PRNEWSWIRE/ -- ORAMED PHARMACEUTICALS INC. (NASDAQ: ORMP) (TASE: ORMP) (WWW.ORAMED.COM), A CLINICAL-STAGE PHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF ORAL DRUG DELIVERY PLATFORMS, TODAY ISSUED A LETTER TO SHAREHOLDERS FROM ITS PRESIDENT AND CHIEF EXECUTIVE OFFICER, NADAV KIDRON. DEAR SHAREHOLDERS, I AM PLEASED TO SHARE WITH YOU AN UPDATE REGARDING ORAMED.

ORAMED LETTER TO SHAREHOLDERS

18-MONTH LOAN WITH INTEREST RATE OF SOFR PLUS 8.5% ORAMED RECEIVES WARRANTS TO PURCHASE UP TO 17 MILLION SHARES OF SCILEX COMMON STOCK THE SENIOR SECURED NOTE WITH SCILEX REPLACES ORAMED'S PREVIOUSLY ANNOUNCED STOCK PURCHASE AGREEMENT AND DIP TERM LOAN WITH SORRENTO THERAPEUTICS NEW YORK , SEPT. 21, 2023 /PRNEWSWIRE/ -- ORAMED PHARMACEUTICALS INC. (NASDAQ: ORMP) (TASE:ORMP) TODAY ANNOUNCED THAT ON SEPTEMBER 21, 2023, ORAMED AND SCILEX HOLDING COMPANY("SCILEX") ENTERED INTO A SECURITIES PURCHASE AGREEMENT PURSUANT TO WHICH SCILEX ISSUED A SENIOR SECURED PROMISSORY NOTE (THE "NOTE") TO ORAMED.

ORAMED ANNOUNCES $101,875,000 SHORT-TERM SENIOR SECURED NOTE TRANSACTION WITH SCILEX HOLDING COMPANY

JV WILL HAVE GLOBAL MARKETING RIGHTS TO ORAL DRUG DELIVERY TECHNOLOGY HTIT TO INVEST $60 MILLION, ORAMED TO INVEST $10 MILLION INTO JV HTIT TO PROVIDE A SUPPLY AGREEMENT FOR ORAL INSULIN CAPSULE JV TO ADVANCE REGISTRATION OF ORAL INSULIN IN THE UNITED STATES AND OTHER COUNTRIES NEW YORK , AUG. 2, 2023 /PRNEWSWIRE/ -- ORAMED PHARMACEUTICALS INC. (NASDAQ: ORMP) (TASE: ORMP) (WWW.ORAMED.COM) ANNOUNCED TODAY THAT IT HAS SIGNED A NON-BINDING TERM SHEET WITH HEFEI TIANHUI BIOTECH CO., LTD. ("HTIT") TO ESTABLISH A JOINT VENTURE ("JV") BASED ON ORAMED'S ORAL DRUG DELIVERY TECHNOLOGY.

Oramed Pharmaceuticals Inc.

ORMP

Price

Financial Reports

No items found.

Press Releases

Oramed Pharmaceuticals Inc.

ORMP.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ORMP